A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.
The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.
Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.
US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.